Nanopolymeric Therapeutics

MRS Bulletin ◽  
2009 ◽  
Vol 34 (6) ◽  
pp. 422-431 ◽  
Author(s):  
Rong Tong ◽  
David A. Christian ◽  
Li Tang ◽  
Horacio Cabral ◽  
James R. Baker ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Cancer Treatment ◽  
Branched Polymers ◽  
Clinical Cancer ◽  
Drug Conjugates ◽  
Delivery Vehicles ◽  
Nanoparticulate Delivery ◽  
Polymer Drug Conjugates ◽  
Made In

AbstractPolymers have been extensively utilized in the design of nanometer-sized delivery vehicles of chemotherapeutics for clinical cancer therapy. Polymeric nanoparticulate delivery vehicles, with chemotherapeutics being either conjugated or encapsulated, have been developed into a variety of different architectures, including polymer-drug conjugates with linear or branched polymers, micelles, and polymersomes. This review describes the progress that has been made in the field of polymeric nanomedicine that brings the science closer to clinical realization of nanopolymeric therapeutics for its application in cancer treatment.

Albumin–Polymer–Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles

2016 ◽  
Vol 5 (10) ◽  
pp. 1089-1094 ◽  
Author(s):  
Anton A. A. Smith ◽  
Kaja Zuwala ◽  
Oliver Pilgram ◽  
Karen Singers Johansen ◽  
Martin Tolstrup ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Vehicles ◽  
Drug Conjugates ◽  
Delivery Vehicles ◽  
Polymer Drug Conjugates ◽  
High Payload

Redox-Responsive Polymer–Drug Conjugates Based on Doxorubicin and Chitosan Oligosaccharide-g-stearic Acid for Cancer Therapy

2015 ◽  
Vol 12 (4) ◽  
pp. 1193-1202 ◽  
Author(s):  
Yigang Su ◽  
Yingwen Hu ◽  
Yongzhong Du ◽  
Xuan Huang ◽  
Jiabei He ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Stearic Acid ◽  
Chitosan Oligosaccharide ◽  
Drug Conjugates ◽  
Redox Responsive ◽  
Responsive Polymer ◽  
Polymer Drug Conjugates

scholarly journals Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers

2021 ◽  
Author(s):  
Haiyong Peng
Keyword(s):  
Cancer Therapy ◽  
Small Molecules ◽  
Pharmaceutical Companies ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Solid Malignancies ◽  
Selective Delivery ◽  
And Performance ◽  
Antibody Drug ◽  
Made In

Abstract Antibody–drug conjugates (ADCs) are targeted therapeutics generated by conjugation of cytotoxic small molecules to monoclonal antibodies (mAbs) via chemical linkers. Due to their selective delivery of toxic payloads to antigen-positive cancer cells, ADCs demonstrate wider therapeutic indexes compared to conventional chemotherapy. After decades of intensive research and development, significant advances have been made in the field, leading to a total of ten FDA-approved ADCs to treat cancer patients. Currently, ~ 80 ADCs targeting different antigens are under clinical evaluation for treatment of either hematological or solid malignancies. Notably, 3 ADCs targeting the same oncofetal protein, ROR1, have attracted considerable attention when they were acquired or licensed successively in the fourth quarter of 2020 by 3 major pharmaceutical companies. Apparently, ROR1 has emerged as an attractive target for cancer therapy. Since all the components of ADCs, including the antibody, linker, and payload, as well as the conjugation method, play critical roles in ADC’s efficacy and performance, their choice and combination will determine how far they can be advanced. This review summarizes the design and development of current anti-ROR1 ADCs and highlights an emerging trend to target ROR1 for cancer therapy.

Amphiphilic polymer–drug conjugates based on acid-sensitive 100% hyperbranched polyacetals for cancer therapy

2017 ◽  
Vol 52 (16) ◽  
pp. 9430-9440 ◽  
Author(s):  
Xiao Duan ◽  
Yalan Wu ◽  
Mengsi Ma ◽  
Junjie Du ◽  
Shan Zhang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Amphiphilic Polymer ◽  
Drug Conjugates ◽  
Polymer Drug Conjugates

Bispecific antibody complex pre-targeted delivery of polymer–drug conjugates for cancer therapy

2012 ◽  
Vol 2 (1) ◽  
pp. 65-76 ◽  
Author(s):  
Keyur S. Gada ◽  
Vishwesh Patil ◽  
Rajiv Panwar ◽  
Arash Hatefi ◽  
Ban-An Khaw
Keyword(s):  
Cancer Therapy ◽  
Targeted Delivery ◽  
Bispecific Antibody ◽  
Drug Conjugates ◽  
Antibody Complex ◽  
Polymer Drug Conjugates

scholarly journals Smart branched polymer drug conjugates as nano-sized drug delivery systems

2015 ◽  
Vol 3 (10) ◽  
pp. 1321-1334 ◽  
Author(s):  
A. Duro-Castano ◽  
J. Movellan ◽  
M. J. Vicent
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Branched Polymers ◽  
Branched Polymer ◽  
Drug Conjugates ◽  
Polymer Drug Conjugates

Branched polymers own special properties derived from their intrinsic characteristics. These properties make them ideal candidates to be used as carriers for an improved generation of polymer-drug conjugates.

scholarly journals Encapsulation of Poorly Soluble Drugs in Polymer-Drug Conjugates: Effect of Dual-Drug Nanoformulations on Cancer Therapy

2014 ◽  
Vol 31 (6) ◽  
pp. 1605-1615 ◽  
Author(s):  
Thulani H. Senanayake ◽  
Yaman Lu ◽  
Anna Bohling ◽  
Srikumar Raja ◽  
Hamid Band ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Poorly Soluble Drugs ◽  
Drug Conjugates ◽  
Poorly Soluble ◽  
Polymer Drug Conjugates ◽  
Dual Drug

scholarly journals Aptamer-Assisted Delivery of Nucleotides with Tumor-Suppressing Properties for Targeted Cancer Therapies

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Pouya Safarzadeh Kozani ◽  
Pooria Safarzadeh Kozani ◽  
Fatemeh Rahbarizadeh
Keyword(s):  
Cancer Therapy ◽  
Cancer Treatment ◽  
Cancer Therapies ◽  
Targeted Cancer Therapy ◽  
Small Interfering Rnas ◽  
Cell Surface Antigens ◽  
Assisted Delivery ◽  
Targeted Cancer Therapies ◽  
Delivery Vehicles ◽  
Significant Attention

: Targeted cancer therapy is developing rapidly according to the fact that it has been demonstrated that this type of therapy can reduce various side effects and adverse events of the commonly available cancer treatment approaches such as chemotherapy and radiotherapy. This selective type of cancer therapy can mediate encouraging outcomes where the frontline cancer treatment methods have failed to do so. Aptamer-assisted delivery of various types of cargoes or the utilization of aptamer for the redirection of delivery vehicles is among various fields of targeted cancer therapy that have gained significant attention lately. Aptamers are single-stranded oligonucleotides or peptide molecules that harbor significant levels of specificity and affinity toward various types of targets such as cell surface antigens, ions, toxins, chemicals, etc. They have shown encouraging results in several types of targeted cancer therapy for the redirection of a variety of cargoes. In this review, we shed the light on the application of aptamers for the delivery of nucleotides such as MicroRNAs (miRNAs), short or small interfering RNAs (siRNAs), and short hairpin RNA or small hairpin RNAs (shRNAs) that harbor tumor suppression properties in various kinds of malignancies.

Sign in / Sign up

Export Citation Format

Share Document